ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 173 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2019. The put-call ratio across all filers is 6.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $418,000 | -24.0% | 10,086 | +33.1% | 0.10% | -35.8% |
Q1 2022 | $550,000 | +67.7% | 7,580 | +94.4% | 0.15% | +32.1% |
Q4 2021 | $328,000 | +11.9% | 3,900 | +20.0% | 0.11% | +17.9% |
Q3 2021 | $293,000 | +20.6% | 3,250 | +27.5% | 0.10% | -5.0% |
Q2 2021 | $243,000 | -40.7% | 2,550 | -29.2% | 0.10% | -60.3% |
Q1 2021 | $410,000 | -27.7% | 3,600 | -72.8% | 0.25% | +17.8% |
Q3 2019 | $567,000 | +34.0% | 13,244 | +50.7% | 0.21% | -48.7% |
Q4 2018 | $423,000 | – | 8,790 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |